Corporate Website
Africa
Argentina
Asia
Australia
Belgium
Brazil
Bulgaria
Canada (EN)
Chile
China
Colombia
Denmark
Egypt
France
Germany
Greece
Hungary
Indonesia
Italia
India
Japan
Korea
Malaysia
Mexico
Middle East
Netherlands
Peru
Philippines
Poland
Portugal
Romania
Russia
South Africa
Spain
Sweden
Thailand
Tunisia
Turkey
Ukraine
United Kingdom
USA
Vietnam
Your search for "result" return 76 results.
Hatchery Vaccination Program >
Ceva Hatchery Immunisation Control Keys Program (C.H.I.C.K. Program)
Vaccination Programs >
Two services to assist the vaccination program at hatchery and in farm
Newcastle disease virus outbreaks: Vaccine mismatch or inadequate application? >
Newcastle disease (ND) is one of the most important diseases of poultry, and may cause devastating losses in the poultry industry worldwide.
C.H.I.C.K. Program Online - No.14 >
Embryo diagnosis - An important tool to help the hatchery manager
Part 1 >
Mycoplasma hyopneumoniae
Lung Scoring Methodology >
Ceva Lung Program is used to determine the appropriate vaccination protocol and monitor the results of vaccination. This brochure will bring insight into slaughter house lung check in pigs.
Coglapix® - Economic benefit study versus an antibiotic in the control of A.P. >
The Vaccine group (with Coglapix®) and Antibiotic group have the higher performance and more profit than the Control group. Although the similar performance, the economic impact given by the Vaccine g...
Mycoplasma hyopneumoniae - still a major challenge >
Mycoplasma hyopneumoniae cannot be ignored warns JOHN BAKER. Vaccination provides immediate improvement in the control of this costly disease and correcting problems in environment and management will...
C.H.I.C.K. Program Online - No.13 >
Spray vaccination: what happens during and after this procedure
APP: Comparison Of Four Different Vaccines Under Field Conditions In The Philippines >
A trial under field conditions has been conducted in the Philippines in comparison Coglapix® with two toxoid vaccines and one bacterin vaccine of the market. In this trial, Coglapix®, the toxoid vacci...